Effectiveness of dupilumab in pediatric patients with a nummular phenotype of atopic dermatitis

Abstract

AbstractThe nummular phenotype of atopic dermatitis is clinically characterized by pruritic, coin‐shaped plaques that are frequently recalcitrant to treatment. In this study, a retrospective chart review was conducted to evaluate the effectiveness and safety of dupilumab in children with nummular lesions of dermatitis. Twelve out of 14 patients demonstrated significant clinical improvement at a median time of 2.5 months (interquartile range, 1–4) after dupilumab initiation. A single case of paradoxical psoriasiform eruption was the only side effect reported in our cohort.